Background and Purpose-Statins reduce the risk of stroke recurrence, but the benefits of statins in improving outcome of acute stroke patients have not been well explored. Methods-We assessed potential effects of statins initiated before or within 4 weeks of stroke on 90-day outcome.
Materials and Methods
The medication records and the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) data were collected from case report forms from the phase 3 citicoline trial and patients were divided into 3 groups: using statins before stroke, started statin after stroke onset, and patients not treated with statins at anytime.
Outcome Measures
Primary favorable outcome was defined as Յ2 on the NIHSS at week 12 after stroke and mRS score Յ2 at 12 weeks.
Statistical Analysis
Univariate statistical analyses ( 2 test for all variables except continuous age variable in which t test was performed) to study the associations of the demographic and medical and risk factors on NIHSS at week 12 (Table 1 ). Significant univariate predictors (PϽ0.05) were included in multivariate stepwise binary logistic regression analysis (Tables 2 and 3) .
Results
Baseline NIHSS in the prestroke statin, poststroke statin, and the group never exposed to statin were 13.1Ϯ3.8, 12.9Ϯ4.1, and 13.1Ϯ3.7, respectively, and were not significantly different. Patients on citicoline were equally distributed in the 3 groups (Table 1) .
There Table 2 .
The results of mRS Յ2 as the outcome measure were similar to the results of the outcomes of NIHSS Յ2. In the univariate analysis, poststroke statins were strong predictor of outcome compared with the other 2 groups ( 2 ϭ9.47; Pϭ0.002). Stroke subtypes besides cardioembolic stroke were independently associated with better outcome ( 2 ϭ11.91; Pϭ0.008). Patients on citicoline (Pϭ0.046) were more likely to have a positive outcome. Hypertension (Pϭ0.009), diabetes (PϽ0.001), cardiac disease (PϽ0.001), previous stroke or transient ischemic attack (Pϭ0.007), or early antihypertensive medication use (PϽ0.001) were associated with poor outcome.
In the multivariate analysis, only statin use after stroke (Pϭ0.033; OR, 1.57; CI, 1.04 to 2.38), treatment with citicoline (Pϭ0.028; OR, 1.39; CI, 1.04 to 1.85), and smallvessel stroke (Pϭ0.008; OR, 2.05; CI, 1.21 to 3.48) were positive and independent predictors of mRS Յ2. Predictors of poor outcome were similar to those on the NIHSS on the mRS Յ2 analysis (Table 3) .
Discussion
Our data suggests that treatment within 4 weeks after acute ischemic stroke with statins was associated with improved Acute lipid-lowering improves outcome from coronary attacks and reduces stroke risk and other properties of statins (improving endothelial function by enhancing endothelial nitric oxide production and antioxidant and anticoagulant effect) may be possible mechanisms of delayed improved outcome, 4 -6 the more likely explanation for poststroke statin use lies in their capability to induce angiogenesis, neurogenesis, and synaptogenesis, factors that may be important in enhancing neuronal recovery and hence stroke outcome. 7, 8 Improved functional outcome at day 14 was demonstrated in Wistar rats treated with atorvastatin beginning 1 day after stroke onset by inducing angiogenesis, neurogenesis, and synaptogenesis by induction of vascular endothelial growth factor, which promotes angiogenesis and brain cGMP, which promotes neurogenesis. 7 These results suggest a potential explanation for the outcome in the group that started statins after stroke onset.
One prestroke statin treatment study demonstrated improved stroke outcome. 9 In our study, prestroke statin use demonstrated a trend toward significance (NIHSS Յ2; Pϭ0.07; OR, 1.07; CI, 0.69 to 1.66). Possible explanations include the short duration of treatment with statins before stroke onset, exclusion of subcortical stroke in the citicoline trial (more likely to have been on statins), and a possible saturation effect on potential enhancers of poststroke recovery in patients that had been on statins before stroke onset. 7 Although previous studies 7, 9 and our t test results are suggestive of the usefulness of statins in improving ischemic stroke outcome, larger prospective trials are needed to confirm these observations.
